Evaluation of CD40 and CD80 receptors in the colonic mucosal membrane of children with inflammatory bowel disease
More details
Hide details
Department of Pediatrics, Pediatric Gastroenterology, Hepatology and Nutrition, Medical University of Gdansk, Poland
Department of Developmental Age Medicine and Paediatric Nursing, Medical University of Bialystok, Poland
Department of Pathomorphology, Medical University of Bialystok, Poland
Barbara Kamińska   

Department of Pediatrics, Pediatric Gastroenterology, Hepatology and Nutrition, Medical University of Gdansk, Poland
Ann Agric Environ Med. 2015;22(4):695–699
The most prevalent inflammatory bowel diseases (IBD) include ulcerative colitis (UC) and Crohn’s disease (CD). Immune processes play a vital role in the etiopathogenesis of these conditions, involving both cellular and humoral response mechanisms. The aim of this study was to quantify CD40- and CD80-positive cells in the biopsy specimens of large intestinal mucosa from children with IBD.

Material and Methods:
The study comprised 38 children aged between 3–17 years (mean 11.5±3.7 years) – 20 boys (52.6 %) and 18 girls (47.4%). Eighteen patients were diagnosed with UC on the basis of clinical manifestation, endoscopic and histopathological findings. Mean age of this subgroup was 11.55±4.07 years. A group of 10 children (mean age 12.30±2.83) diagnosed with CD was also included. The control group comprised 10 IBD-free children (mean age 10.28±4.07 years). The surface expressions of CD40 and CD80 were analyzed in large intestine mucosa biopsy specimens, fixed in formaldehyde, embedded in paraffin, and cut with a microtome into 4 µm slices.

The number of CD40- and CD80-positive cells in the large intestinal mucosa of children with Crohn’s disease and ulcerative colitis was significantly higher than in the controls. The highest number of CD40+ and CD80+ cells was observed in the caecal mucosal membrane of Crohn’s disease patients and in the rectal mucosa of individuals with ulcerative colitis.

IBD is characterized by elevated, segment-specific, expression of CD40 and CD80.

Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007; 369: 1627–1640.
Polese L, Angriman I, Scarpa M, Norberto L, Sturniolo GC, Cecchetto A, et al. Role of CD40 and B7 costimulators in inflammatory bowel diseases. Acta Biomed. 2003; 74 Suppl 2: 65–70.
IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis – the Porto criteria. J Pediatr Gastroenterol Nutr. 2005; 41(1): 1–7.
Nieuwenhuis EE, Escher JC. Early onset IBD: what’s the difference? Dig Liver Dis. 2008; 40(1): 12–15.
Bousvaros A, Antonioli DA, Colletti RB, Dubinsky MC, Glickman JN, Gold BD, et al. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn’s and Colitis Foundation of America. J Pediatr Gastroenterol Nutr. 2007; 44(5): 653–674.
Freeman HJ. Comparison of longstanding pediatric-onset and adult-onset Crohn’s disease. J Pediatr Gastroenterol Nutr. 2004; 39(2): 183–186.
Grzybowska-Chlebowczyk U, Pająk J, Woś H, Gabryel B, Więcek SMK. Ocena stężenia TNF-α w surowicy dzieci z nieswoistymi zapaleniami jelit. Przegl Gastroenterol. 2008; 3: 149–153 (in Polish).
Gruchlik A, Chodurek EZD. Rola miofibroblastów w chorobach zapalnych jelit i procesach nowotworzenia. Przegl Gastroenterol. 2011; 6: 353–358 (in Polish).
Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989; 298(6666): 82–86.
Turner D, Otley AR, Mack D, Hyams J, de Bruijne J, Uusoue K, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology. 2007; 133(2): 423–432.
Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006; 55(6): 749–753.
Bernstein CN, Fried M, Krabshuis JH, Cohen H, Eliakim R, Fedail S, et al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis. 2010; 16(1): 112–124.
Daperno M, D’Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc. 2004; 60(4): 505–512.
Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011; 17(6): 1314–1321.
Turner D, Griffiths AM, Walters TD, Seah T, Markowitz J, Pfefferkorn M, et al. Appraisal of the pediatric Crohn’s disease activity index on four prospectively collected datasets: recommended cutoff values and clinimetric properties. Am J Gastroenterol. 2010; 105(9): 2085–2092.
Grzybowska K. Udział układu immunologicznego w patogenezie nieswoistych zapaleń jelit u dzieci. Nowa Pediatria. 2003; 1: 81–84 (in Polish).
Brown SJ, Mayer L. The immune response in inflammatory bowel disease. Am J Gastroenterol. 2007; 102(9): 2058–2069.
Danese S, Sans M, Fiocchi C. The CD40/CD40L costimulatory pathway in inflammatory bowel disease. Gut. 2004; 53(7): 1035–1043.
Battaglia E, Biancone L, Resegotti A, Emanuelli G, Fronda GR, Camussi G. Expression of CD40 and its ligand, CD40L, in intestinal lesions of Crohn’s disease. Am J Gastroenterol. 1999; 94(11): 3279–3284.
Polese L, Angriman I, Cecchetto A, Norberto L, Scarpa M, Ruffolo C, et al. The role of CD40 in ulcerative colitis: histochemical analysis and clinical correlation. Eur J Gastroenterol Hepatol. 2002; 14(3): 237–241.
Vogel JD, West GA, Danese S, De La Motte C, Phillips MH, Strong SA, et al. CD40-mediated immune-nonimmune cell interactions induce mucosal fibroblast chemokines leading to T-cell transmigration. Gastroenterology. 2004; 126(1): 63–80.
Liu Z, Colpaert S, D’Haens GR, Kasran A, de Boer M, Rutgeerts P, et al. Hyperexpression of CD40 ligand (CD154) in inflammatory bowel disease and its contribution to pathogenic cytokine production. J Immunol. 1999; 163(7): 4049–4057.
Carlsen HS, Yamanaka T, Scott H, Rugtveit J, Brandtzaeg P. The proportion of CD40+ mucosal macrophages is increased in inflammatory bowel disease whereas CD40 ligand (CD154)+ T cells are relatively decreased, suggesting differential modulation of these costimulatory molecules in human gut lamina propria. Inflamm Bowel Dis. 2006; 12(11): 1013–1024.
Sawada-Hase N, Kiyohara T, Miyagawa J, Ueyama H, Nishibayashi H, Murayama Y, et al. An increased number of CD40-high monocytes in patients with Crohn’s disease. Am J Gastroenterol. 2000; 95(6): 1516–1523.
Borcherding F, Nitschke M, Hundorfean G, Rupp J, von Smolinski D, Bieber K, et al. The CD40-CD40L pathway contributes to the proinflammatory function of intestinal epithelial cells in inflammatory bowel disease. Am J Pathol. 2010; 176(4): 1816–1827.
Danese S, Sans M, Scaldaferri F, Sgambato A, Rutella S, Cittadini A, et al. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn’s disease. J Immunol. 2006; 176(4): 2617–2624.
Hart AL, Al-Hassi HO, Rigby RJ, Bell SJ, Emmanuel AV, Knight SC, et al. Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology. 2005; 129(1): 50–65.
Perminow G, Reikvam DH, Lyckander LG, Brandtzaeg P, Vatn MH, Carlsen HS. Increased number and activation of colonic macrophages in pediatric patients with untreated Crohn’s disease. Inflamm Bowel Dis. 2009; 15(9): 1368–1378.
Maerten P, Liu Z, Ceuppens JL. Targeting of costimulatory molecules as a therapeutic approach in inflammatory bowel disease. BioDrugs. 2003; 17(6): 395–411.
Rugtveit J, Bakka A, Brandtzaeg P. Differential distribution of B7.1 (CD80) and B7.2 (CD86) costimulatory molecules on mucosal macrophage subsets in human inflammatory bowel disease (IBD). Clin Exp Immunol. 1997; 110(1): 104–113.